Acute Bacterial Exacerbation of Chronic Bronchitis (ABECB) (DBCOND0040791)

Identifiers

Synonyms

Acute Bacterial Exacerbation of Chronic Bronchitis / Bronchitis bacterial / Septic bronchitis (disorder) / Bronchitis bacterial NOS

Associated Data

Indicated Drugs and Targets

Drug	Description	Targets
Cefditoren	A broad-spectrum third-generation cephalosporin antibiotic typically used to treat bacterial infections of the skin and respiratory tract.	Penicillin-binding protein 1Atarget Penicillin-binding protein 2Btarget
Cefpodoxime	A third-generation cephalosporin antibiotic used in the treatment of various bacterial infections, including gonorrhea, community acquired pneumonia, and sinusitis.	Peptidoglycan synthase FtsItarget
Cefprozil	A cephalosporin antibiotic used in the treatment of various bacterial infections, such as pharyngitis, tonsillitis, otitis media, and uncomplicated skin infections.	Penicillin-binding protein 1Atarget Penicillin-binding protein 2xtarget Penicillin-binding protein 2Btarget
Ceftibuten	A third-generation cephalosporin antibiotic commonly used in the treatment of acute bacterial exacerbations of chronic bronchitis (ABECB), acute bacterial otitis media, pharyngitis, and tonsillitis.	Solute carrier family 15 member 1transporter Solute carrier family 15 member 2transporter Peptidoglycan synthase FtsItarget Penicillin-binding protein 1Atarget Penicillin-binding protein 1Btarget Penicillin-binding protein 2target Solute carrier family 22 member 6transporter Organic anion transporter 3transporter
Cefuroxime	A cephalosporin indicated for the treatment of a variety of infections including acute bacterial otitis media, several upper respiratory tract infections, skin infections, urinary tract infections, gonorrhea, early Lyme disease, and impetigo.	Penicillin-binding protein 1Atarget Solute carrier family 15 member 1transporter Solute carrier family 15 member 2transporter
Clarithromycin	A macrolide antibiotic used for the treatment of a wide variety of bacterial infections such as acute otitis, pharyngitis, tonsillitis, respiratory tract infections, uncomplicated skin infections, and helicobacter pylori infection.	50S ribosomal protein L10target Cytochrome P450 3A4enzyme Cytochrome P450 3A5enzyme ATP-dependent translocase ABCB1transporter Solute carrier family 22 member 7transporter Voltage-gated inwardly rectifying potassium channel KCNH2target Solute carrier organic anion transporter family member 1B1target Solute carrier organic anion transporter family member 1B3target Bile salt export pumptransporter Solute carrier organic anion transporter family member 1B1transporter Solute carrier organic anion transporter family member 1B3transporter
Gemifloxacin	A quinolone antibacterial agent used for the treatment of acute bacterial exacerbation of chronic bronchitis and mild to moderate community-acquired pneumonia caused by susceptible bacteria.	DNA gyrase subunit Atarget DNA topoisomerase 4 subunit Atarget Cytochrome P450 1A2enzyme DNA gyrase subunit Atarget DNA gyrase subunit Btarget
Lomefloxacin	A fluoroquinolone used to prevent and treat a wide variety of infections in the body.	DNA gyrase subunit Atarget DNA topoisomerase 4 subunit Atarget DNA topoisomerase 2-alphatarget Cytochrome P450 1A2enzyme Organic cation/carnitine transporter 2transporter ATP-binding cassette sub-family C member 2transporter DNA topoisomerase 2-betatarget
Ofloxacin	An antibacterial agent used for the treatment of bacterial infections in many parts of the body, including the respiratory tract, kidney, skin, soft tissue, and urinary tract.	DNA gyrase subunit Atarget DNA topoisomerase 4 subunit Atarget DNA topoisomerase 2-alphatarget Cytochrome P450 1A2enzyme Organic cation/carnitine transporter 2transporter Multidrug resistance-associated protein 1transporter Solute carrier family 22 member 6transporter ATP-binding cassette sub-family C member 2transporter Solute carrier family 22 member 4transporter Bile salt export pumptransporter DNA gyrase subunit Atarget DNA gyrase subunit Btarget

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT00645086	Comparative Study of 5 Days of M02-472 Clarithromycin Extended-Release Tablets to 7 Days of Clarithromycin Immediate-Release Tablets for the Treatment of Exacerbation of Chronic Bronchitis	Clarithromycin	treatment	3	completed